Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

Add Yahoo as a preferred source to see more of our stories on Google. A Novartis sign hangs on the side of an office building in Cambridge, Massachusetts. Novartis’ radiopharmaceutical drug Pluvicto ...

After abandoning plans for a Nasdaq IPO back in 2024, Telix made a concerted effort to bolster its radiopharma prowess, ...

Novartis got a clinical data boost that could support its radiotherapy Pluvicto’s $2 billion-plus peak sales ambition. Pluvicto helped patients with previously treated PSMA-positive metastatic ...

Good morning. Today, we’re looking at mixed reactions to a closely watched immunology trial and growing scrutiny of a type of ...

By Bhanvi Satija May 31 (Reuters) - Novartis said on Sunday that early data from its experimental actinium-based drug showed ...

Novartis has pushed its second radioligand therapy over the FDA finish line, and the Swiss pharma has more than $2 billion in peak sales expectation linked to the new launch. Wednesday, the FDA ...

- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists ...

Treatment with Pluvicto following ARPI resulted in favorable progression and response outcomes in PSMA-positive mCRPR. Among patients with prostate-specific membrane antigen (PSMA)-positive metastatic ...

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed. Patients ...

Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported last week. Novartis, the pharmaceutical company that manufactures Pluvicto, ...

Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who ...